Endocrine Abstracts

Introduction: Embryonal antitumour modulator of Mkrtchyan (EATM) reveals a hypoglycemic effect in streptozotocin-induced diabetes in rats. The aim of the work was to determine the influence of EATM on the process of releasing of Nox of erythrocyte membranes (EM) and serum of patients with diabetes type 1 and 2.

Materials and methods: The study included 12 patients with type 1 diabetes, 12 patients with type 2 diabetes and 12 healthy volunteers. Isolation of Nox fractions of purified EM and blood serum was performed by ion-exchange chromatography. The Nox amount was determined at 530 nm. O₂⁻-producing activity of Nox isoforms was determined by nitrotetrazolium blue. The statistical analysis was performed by one-way ANOVA. The study was approved by the Local Ethics Committee of the YSMU.

Results: It was shown, that the Nox release in EM of type 2 and 1 diabetes is higher by 83.3±7.4% and 58.4±6.5%, respectively, compared with donor blood. The addition of EATM resulted in suppression of the process of the Nox release in EM in diabetes type 2 and 1 and healthy donors by 45.5±6.2%, 31.6±4.4% and 25.1±3.7%, respectively. In the same conditions the increase of releasing of the extracellular Nox from the blood serum in diabetes type 2 and 1 is up by 109.2±8.7% and 45.4±5.5% respectively. Addition of EATM reduced activity of eNox by 47.9±4.4%, 31.3±2.9% and 29.3±3.2%, respectively.

Conclusion: The suppression of the releasing Nox and eNox of EM and serum exosomes in diabetes type 1 and 2 may be apparently a novel mechanism of membrane stabilising effect of the EATM ex vivo. This gives some scientific term for EATM as an agent, which helps to stabilise the EM and exosomes in diabetes type 1 and especially type 2 in vivo.